Type 2 diabetes patients who took insulin degludec showed lower rates of overall hypoglycemic episodes per year than their counterparts who received insulin glargine, according to two Phase III studies in The Lancet. Researchers also found that patients with type 1 or type 2 diabetes who were on degludec treatment had a 25% reduction in nocturnal hypoglycemia rates compared with those who took glargine.
Degludec fares better than glargine in glucose control
SmartBrief Job Listings for Health Care
|Health Economics & Reimbursement Manager - Transcatheter Heart Valve||
|Sr. Medical Device Reimbursement Specialist - Regional||
|Fort Worth , TX|
|Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group||
|Clinical Trials Agreements Specialist (209955)||
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
|SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST||
Matheson Tri-Gas, Inc.